BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $861,851 | +54.1% | 32,683 | +0.5% | 0.00% | +100.0% |
Q2 2023 | $559,224 | -5.2% | 32,513 | -8.6% | 0.00% | 0.0% |
Q1 2023 | $589,966 | +117.6% | 35,583 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $271,142 | -35.1% | 35,583 | -15.5% | 0.00% | 0.0% |
Q3 2022 | $418,000 | +9.4% | 42,093 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $382,000 | -10.5% | 42,093 | +0.0% | 0.00% | 0.0% |
Q1 2022 | $427,000 | -39.2% | 42,083 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $702,000 | -64.4% | 42,083 | -0.0% | 0.00% | -75.0% |
Q3 2021 | $1,972,000 | -22.4% | 42,084 | +0.9% | 0.00% | -20.0% |
Q2 2021 | $2,542,000 | +14.9% | 41,704 | +16.1% | 0.01% | +25.0% |
Q1 2021 | $2,213,000 | -2.9% | 35,922 | +12.0% | 0.00% | -20.0% |
Q4 2020 | $2,280,000 | +78.8% | 32,060 | -5.6% | 0.01% | +66.7% |
Q3 2020 | $1,275,000 | +27.5% | 33,970 | +10.7% | 0.00% | +50.0% |
Q2 2020 | $1,000,000 | +123.7% | 30,680 | +99.2% | 0.00% | +100.0% |
Q1 2020 | $447,000 | – | 15,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |